Ischemic Cerebral Stroke Market: Overview
Ischemic cerebral stroke occurs when blood vessels that supply blood to brain are blocked due to the formation of blood clots resulting in the corresponding loss of neurologic function. The symptoms of ischemic cerebral stroke complains include the abrupt onset of hemiparesis, quadriparesis and monoparesis, monocular visual loss, diplopia, visual field deficits, hemisensory deficits, dysarthria, facial droop, vertigo, ataxia, nystagmus, aphasia and decrease in the level of consciousness.
Ischemic Cerebral Stroke Market: Segmentation
Ischemic cerebral stroke market can be segmented on the basis of the diagnostic techniques and treatments available. On the basis of the diagnostic techniques, ischemic cerebral stroke market is classifies into following segments:
CT scan is the most common technique, which is used for diagnosis of ischemic cerebral stroke, majorly due to its efficiency to capture the images in the form of axial slices or as volume studies in three-dimensional form. These three-dimensional images provide the doctor, better insight about the stroke condition. In addition to imaging diagnosis, doctors also perform lumbar puncture and other laboratory testing such as complete blood count, basic chemistry panel, coagulation studies and toxicology screening. These tests are performed to discover any additional disease condition which could hinder the treatment such as meningitis, coagulopathy and other concurrent illness such as diabetes, hypoglycemia, renal insufficiency and hyponatremia.
On the basis of the treatment, the ischemic cerebral stroke market is majorly classified into two classes namely medication treatment and surgical treatment. Surgical treatment involves the removal of the blood clots and fatty deposits from the artery in the neck. The surgery helps in reducing the risk of another stroke, but this method of treatment is not suitable for everyone. Therefore, medications capture the major share of the ischemic cerebral stroke treatment market. Drugs that are usually prescribed for treatment include:
Alteplase captures the major share of the ischemic cerebral stroke medication market followed by warfarin. Alteplase is used to break up blood clots and for restoring blood flow in the brain while warfarin prevents formation of blood clot. Aspirin and clopidrogel are prescribed to reduce the rate of formation of blood clots after a stroke. Moreover, many market players in ischemic cerebral stroke market are performing research for developing drugs that take less time for breaking blood clots and restoring blood flow. For instance, Stempeutics Research Pvt., Ltd. has developed a drug with the namely Stempeucel which is expected to show efficient results in the forecast period leading to the growth of ischemic cerebral stroke market. Currently, Stempeucel is under phase II clinical trials for treatment of ischemic cerebral stroke.
Ischemic Cerebral Stroke Market: region-wise Insight
North America leads the ischemic cerebral stroke market followed by Europe majorly due to high prevalence of ischemic cerebral stroke. According to the Centers for Disease Control and Prevention (CDC), stroke is a leading cause of death in U.S. and kills around 130,000 people every year and around 85% of the strokes are ischemic cerebral stroke. Such high prevalence of the disease leads to the increased need for diagnosis and treatment medications resulting in the growth of ischemic cerebral stroke market.
Asia-Pacific is growing rapidly in the ischemic cerebral stroke treatments market due to increasing prevalence of the disease and growing government support for spreading awareness about ischemic cerebral stroke. As for instance, in 2008, the Regional Comprehensive Stroke Center (CSC) program in South Korea was initiated by the Ministry of Health and Welfare of South Korea to spread awareness about the availability of treatments and to decrease the mortality rate of the stroke nationwide.
Ischemic Cerebral Stroke Market: Key Players
Other major players in the ischemic cerebral stroke market include Bayer AG, Boehringer Ingelheim GmbH, H. Lundbeck A/S, Bristol-Myers Squibb Company, ThromboGenics NV, Vernalis plc and Neurotec Pharma SL.
The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.
The study is a source of reliable data on:
The regional analysis covers:
TMR estimates the market size of various sectors using a combination of available data on the number and revenue of companies within each sub-sector and tiers of companies. The basic components used to determine market size and forecast for a specific product area are not only limited to supply-side data, but are also related to demand, industry trends, and the economic outlook. All the above data points are utilized to generate a statistical model targeting the sector marketplace. More than 300 TMR analysts across the world integrate these elements into a framework to determine the subsector market size for a base year and then forecast growth within each market.
TMR regularly interviews technology and business professionals as an ongoing effort to track the latest developments within each sector. These continuous surveys are stratified by company size and industry segment and weighted to reflect the global market place. All data are collected on an ongoing effort through a structured questionnaire rolled over the web or conducted via telephones. This provides the TMR team opportunities to request for detailed question sets, complex skip patterns, and real-time calculations, which assists respondents in answering questions involving numbers and percentages. Respondents, who are interviewed as experts, are screened and qualified based on certain criteria in addition to their decision-making authority and the scope of activity within their organizations.
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.
Please fill the Request TOC form below.
Make an enquiry before buying this Report
Please fill the enquiry form below.